Diabetic patients with severe autonomic nervous disorder show delayed gastric emptying accompanied by diabetic gastroparesis, which decreases the electric activity of the stomach associated with gastric motility. It is reported that epalrestat, an aldose reductase inhibitor, is useful for treating diabetic neuropathy. Therefore, we evaluated whether this drug improves the decreased gastric motility in diabetic patients.
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Methods The present study evaluated the electrogastrograms (EGG) and autonomic nervous activity in 15 healthy volunteers (N group), and in 15 diabetic patients before and after the administration of epalrestat (DM group). Autonomic nervous activity was evaluated by spectral analysis of heart rate variability.
The EGGs were recorded before and after oral administration of epalrestat (3 months or more) in the DMgroup. Results The dominant frequency of EGGwas 3 cycles/min (cpm) in the N group. However, these 3 cpm waves disappeared with bradygastria, and postprandial increases in the peak powers of EGGwere not observed in the DMgroup. Both the amplitude of 3 cpmwaves and the postprandial peak powers were significantly increased after the administration of epalrestat. The parameters of autonomic nervous activities (LF power, HF power, and the LF/HFratio) were significantly lower in the DMgroup before the administration of epalrestat than in the N group. However, these parameters were improved after the administration of epalrestat. Conclusion Since gastroparesis is a form of diabetic dysautonomia, complication by gastroparesis may influence blood sugar control and the absorbance of oral antidiabetics.
Epalrestat significantly increased the amplitude of 3 cpm waves on EGGand improved the spectral analytical parameters of heart rate variability. These findings suggest that epalrestat is useful for the treatment of diabetic gastroparesis.
Introduction
Diabetic gastroparesis was first reported by Rundles (1) in 1945, and Kassander (2) named the condition gastroparesis diabeticorum in 1958. Diabetic patients with severe autonomic nervous disorder show delayed gastric emptying accompanied by gastroparesis, which decreases electric activities of the stomach associated with gastric motility (3).
There have been many reports that epalrestat, an aldose reductase inhibitor, is useful for treating diabetic neuropathy (4, 5) . However, the effect of epalrestat on gastric motility has not been studied extensively in diabetic patients. The present study evaluated the gastric motility and autonomic nervous activity using electrogastrography (EGG) and spectral analysis of heart rate variability before and after the administration of epalrestat.
Methods

Subjects
The subjects consisted of 15 healthy volunteers (N group: 8 men and 7 women; mean age, 56.3±6.5 years) and 15 patients with type 2 diabetes mellitus (DMgroup: 7 men and 8 women; mean age, 59.1±7.8 years). Subjects of the N group had no history of cardiac disorder, no physiological abnormalities, a systolic blood pressure of <140 mmHg,a diastolic blood pressure of <90 mmHgat rest, normal standard ECG, a normal chest X-ray, and normal results of urinalysis, hematological and biochemical examinations. Diabetic patients who fulfilled the following inclusion criteria were diagnosed as having type 2 diabetes mellitus and enrolled in the DMgroup: those showing venous fasting plasma glucose levels >126 mg/dl, those showing plasma glucose levels >200mg/dl at 2 hours after oral administration of 75 g of glucose (75 g OGTT), or those showing increased casual plasma glucose levels (>200 mg/dl) on two or more occasions. EGGwere serially recorded. Before the examination, written informed consent was obtained from all subjects.
Percutaneous electrogastrography
The EGGwas recorded using a portable electrogastrographic recorder (NIPRO EG; A&D, Tokyo, Japan). As shown in Fig. 1 cycle/min (cpm). Data recording was 13 bit, and the influence of respiration was completely removed using band-pass filter between 2.1 cpm (roll-off, 18 dB/octave) and 5.4 cpm (roll-off, 48 dB/octave). In addition, the influence of body movement was minimized using a linear phase filter to decrease the strain of EGGsignals (6) . EGG data were transferred to a personal computer (Windows 2000) via RC232C, and 512 data sets were analyzed by fast Fourier transformation (FFT) using EG soft- Percutaneous EGGwas serially recorded from 1 hour before to 90 minutes after the meal. In the DMgroup, the EGG was recorded again more than 3 months (mean administration duration, 125.6±25.6 days) after the oral administration of epalrestat (150 mg/day) ( Table 1 ).
Spectral analysis of heart rate variability Simultaneous with the recording of percutaneous EGG, 2-channel Holter's ECGs (CM5 and CC5 leads) were recorded in the supine position to avoid the influence of positional changes using a Holter's ECG recorder (SM-50; Fukuda Denshi Co., Ltd., Tokyo, Japan). Holter's ECGs recorded on magnetic tapes were analyzed using a Holter's ECGanalyzer (DMW-9000H), and the data on ECG R-R intervals were input to a personal computer (Windows 2000) via an RS232Ccable and analyzed using time-series data-analysis software (Fukuda Denshi Co.). During spectral analysis of heart rate variability, 5 12 heart rate data were analyzed based on low frequency components (LF power, 0.04-0.15 Hz), high frequency components (HF power, 0.15-0.40 Hz), and the LF/HF ratio. Extra and missing beats were excluded from analysis of the R-Rintervals. Wemeasured LF power, HF power and LF/HF ratio at 6 intervals every hour, and these three parameters were averaged FFT analysis of EGGwaves showed a dominant frequency of 3.2 cpm and a mean peak power amplitude of about 230 juV during fasting. However, EGGwaves at 30 minutes after a meal showedan increased amplitude compared to those obtained during fasting. FFT analysis demonstrated that the dominant frequency and meanpeak power amplitude of EGGwaves obtained 30 minutes after a meal (3.3 cpm and 300 |uV, respectively) were larger than those obtained during fasting.
EGGwaves and FFT analysis in the DMgroup Figure 3 showsthe representative case of EGGwavesand the results of FFTanalysis obtained during fasting and 30 minutes after a meal in the diabetic patients. The regularity of the 3 cpm waves observed in healthy subjects was disturbed in the EGGwaves obtained both during fasting and postprandially in the diabetic patients. FFT analysis demonstrated a decreased peak power amplitude of 3 cpm waves during fasting, in addition to the presence of peak waves at a frequency below 2. Comparison of FFT analysis on EGGwaves between the N and DMgroups before and after the administration of epalrestat Figure 5 shows the comparison of peak power amplitudes obtained by FFT analysis of three frequency ranges, bradygastria (<2.4 cpm), normogastria (2.4-3.6 cpm), and tachygastria (>3.6 cpm), in the N and DMgroups before and after the administration of epalrestat. Although the peak power amplitude did not significantly increase during tachygastria, the peak power amplitude during normogastria (2.4-3.6 cpm) was significantly lower in the DMgroup before epalrestat administration than in the N group. Moreover, the peak power amplitude during bradygastria (<2.4 cpm) was decreased after the administration of epalrestat in the DMgroup. Figure 6 shows the comparison of 3 cpm peak power amplitudes between the Nand DMgroups before and after a meal. The peak power amplitudes were significantly increased in the N group after a meal, but not in the DMgroup. However, postprandial increases in peak power amplitudes were observed in the DMgroup after the administration of epalrestat. Comparison of spectral analysis of heart rate variability between the N and DMgroups before and after the administration of epalrestat with bradygastria (r=-0.63, p<0.05) (Fig. 9) . However, there were no significant correlations among LF power, the LF/HF ratio, and the respective EGGparameters.
Effects of Epalrestat on Gastroparesis
Discussion
Gastroparesis is a form of diabetic dysautonomia that occurs in 20-50% of diabetic patients (7, 8) . Patients with gastroparesis are often asymptomatic, but diabetic gastroparesis may influence the absorption of oral antidiabetics and glycemic control. Although aldose reductase inhibitors have been reported to be useful for treating diabetic neuropathy, few studies have evaluated their effects on diabetic gastroparesis.
In the present study, epalrestat, an aldose reductase inhibitor, significantly increased the number of 3 cpm waves on EGGand improved the spectral analytical parameters of heart rate variability, suggesting that epalrestat may be useful for the treatment of diabetic gastroparesis.
EGGwaves in patients with diabetic gastroparesis and the effects of epalrestat Since the gastric pacesetter potential is disturbed by an autonomic nervous disorder, diabetic patients complicated by dysautonomia frequently complain of nausea, epigastric fullness, regurgitation, and bloating, in addition to hyperglycemia and delayed gastric emptying (9) . However, it has been reported that examination of autonomic nervous functions and glycosylated hemoglobin are not useful for predicting the occurrence of diabetic gastroparesis (10) (11) (12) , and that the manifestation of subjective symptoms is not significantly correlated with the severity of visceral neuropathy. Other studies, however, have reported that the occurrence of diabetic gastroparesis was closely related to the results of heart rate variability analysis (13, 14) . These findings suggest that the treatment of diabetic gastroparesis should be initiated from the early stage and before the appearance of subjective symptoms, based on the results of an easy and simple assessment of gastrointestinal motility.
Previously, nuclear scintigraphy, the gastric tube method, contrast-enhanced roentgenography, the acetoaminophen method, real-time ultrasonography, and MRIwere reported to be useful for evaluating gastric motility (15) (16) (17) (18) . Recently, the usefulness of EGGhas also been reported (19) (20) (21) (22) perimentally, it has been demonstrated that EGGpatterns are similar to electrical activities and motion patterns directly recorded on the mucosalor serous surface of the stomach. A decrease in the amplitude of 3 cpm waves and an increase in the size of spectral componentsof bradygastria and tachygastria by EGGhave been reported in patients with diabetic gastroparesis (23) . In the present study, the DMgroup showeda decrease in the amplitude of 3 cpmwaves and a significant increase in the amplitude of abnormal spectral components of bradygastria before the administration of epalrestat, resulting in the observation of a bimodal FFT wave. However,the spectra of normogastria around 3 cpm increased after the administration of epalrestat, suggesting the improvementof diabetic gastroparesis. Increased polyol metabolism is likely to be involved in the development of diabetic neuropathy. Since it inhibits polyol metabolism, epalrestat has been reported to be useful for relieving numbness, pain, abnormal paresthesia, and abnormal heart rate variability induced by diabetic neuropathy (5) . Though there have been no previous studies on the efficacy of epalrestat for diabetic gastroparesis, the present results suggest that epalrestat should also be useful for treatment of this condition.
Effects of epalrestat on spectral analytical parameters of heart rate variability Heart rate variability is a useful index for evaluating the influence of the autonomic nervous system on cardiac rhythm. And in recent years, the spectral analysis of heart rate variability has been greatly facilitated by the advances in personal computers. Spectral analyses of heart rate variability have revealed two peaks: LF power (0.04-0.15 Hz) and HF power (0.15-0.40 Hz). LF power reflects sympathetic nervous activity modified by parasympathetic nerves, while HFpower reflects parasympathetic nervous activity. In addition, the LF/HFratio may reflect the balance of sympathetic nervous activity (24-30).
In a study by Howorkaet al (31) , spectral analysis of heart rate variability in diabetic patients revealed decreases in the power spectra. In the present study, spectral analysis of heart rate variability before the administration of epalrestat showed decreased LF and HFpowers, which were improved after the administration of epalrestat. Strict blood sugar control is important in patients with diabetic dysautonomia. However, previous studies have confirmed that epalrestat is useful for improving or preventing the development of diabetic cardiac dysautonomia, because epalrestat inhibits polyol metabolism.
Correlation between spectral analysis of heart rate variability and gastric motility It has been reported that diabetic gastroparesis is not associated with indices of diabetic dysautonomia. However, Nakamuraet al (13) reported that coefficients of variation (CVr.r) obtained by time-domain analysis of heart rate variability were closely correlated with gastric motility evaluated by the acetoaminophen and isotope methods. Furthermore, Ziegler et al (14) reported that gastric motility evaluated by the [13C]octanoic acid breath test was correlated with dysautonomia evaluated by CVR-R.However, few studies have reported on the relationship betweenthe spectral analytical parameters of heart rate variability and gastric motility. In the present study, HF power, an index of parasympathetic nerve functions, was significantly correlated with peak power values of EGGand gastric motility at a frequency between 2.4 and 3.6 cpm. Patients with diabetic gastroparesis are often asymptomatic during the early stage.
